EUVIMEDObjevte EUVIMED
Open access

TLR9-activating cholesterol azetidine derivative–assisted therapeutic vaccines for cancer immunotherapy

Junbin Chen iD, Miao Su iD, Boya Yu, Mingda Yang iD, Huiye Wang, Xianzhu Yang iD, Jun Wang iD

Science Advances · 2026

DOI: 10.1126/sciadv.aeb2465 ↗

At a glance

Journal article in Science Advances, 2026. Written by Junbin Chen and 6 co-authors. Institution: School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong 511442, P. …. Major MEDLINE topics: Toll-Like Receptor 9, Cancer Vaccines, Azetidines, Cholesterol. Cited 2 times so far (Crossref); 44 references. The full text is freely available in PubMed Central. Funded by: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Guangzhou Key Research and Development-Program.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Therapeutic cancer vaccines show great promise for de novo induction of antigen-specific T cell responses against tumors. However, weak coordination between innate immune activation and antigen delivery remains a major obstacle to vaccine efficacy. Here, we present a cholesterol azetidine derivative–assisted polymeric carrier, Aze-Chol NP, which stimulates innate immunity and primes tumor-specific CD8 + T cell responses. Mechanistically, Aze-Chol NP induces maturation and activation of dendritic cells (DCs) through the Toll-like receptor 9 (TLR9) pathway while simultaneously delivering protein or peptide antigens to DCs in lymph nodes. The Aze-Chol NP–based nanovaccines markedly inhibited tumor growth and prolonged survival in melanoma and human papillomavirus tumor models. Moreover, combining the nanovaccine with an anti–PD-L1 antibody produced a strong synergistic effect and long-term immune memory, achieving 80% survival beyond 100 days and complete rejection of tumor cell rechallenge. Overall, our study demonstrates that this TLR9-activating carrier provides an effective and straightforward strategy for developing potent cancer vaccines.

Subjects

MeSH terms (MEDLINE)

Toll-Like Receptor 9Cancer VaccinesAzetidinesCholesterolImmunotherapyAnimalsMiceDendritic CellsHumansNanovaccinesToll-Like Receptor AgonistsCD8-Positive T-LymphocytesFemaleCell Line, Tumor

Substances

Toll-Like Receptor 9Cancer VaccinesAzetidinesCholesterolNanovaccinesToll-Like Receptor Agonists

Authors and institutions

  • School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong 511442, P. R. China.
  • National Engineering Research Center for Tissue Restoration and Reconstruction, and Guangdong Provincial Key Laboratory of Biomedical Engineering, South China University of Technology, Guangzhou, Guangdong 510006, P. R.…

ORCID profiles: Junbin Chen, Miao Su, Mingda Yang, Xianzhu Yang, Jun Wang

Funding

  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Guangzhou Key Research and Development-Program

Cite

APA

Chen, J., Su, M., Yu, B., Yang, M., Wang, H., Yang, X., & Wang, J. (2026). TLR9-activating cholesterol azetidine derivative–assisted therapeutic vaccines for cancer immunotherapy. Science Advances. https://doi.org/10.1126/sciadv.aeb2465

Vancouver

Chen J, Su M, Yu B, Yang M, Wang H, Yang X, et al. TLR9-activating cholesterol azetidine derivative–assisted therapeutic vaccines for cancer immunotherapy. Science Advances. 2026. doi:10.1126/sciadv.aeb2465

BibTeX
@article{Chen2026,
  author = {Chen, Junbin and Su, Miao and Yu, Boya and Yang, Mingda and Wang, Huiye and Yang, Xianzhu and Wang, Jun},
  title = {TLR9-activating cholesterol azetidine derivative–assisted therapeutic vaccines for cancer immunotherapy},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aeb2465}
}
Start for free →